SOURCE: World Street Fundamentals

July 05, 2011 09:18 ET

Healthy and Strong - Equity Research on Osiris Therapeutics, Inc. and Biogen Idec Inc.

HONG KONG--(Marketwire - Jul 5, 2011) - Today, released its industry report highlighting Osiris Therapeutics, Inc. (NASDAQ: OSIR) and Biogen Idec Inc. (NASDAQ: BIIB). Full fundamental and technical analysis is available at

While it is thought that the recent healthcare reform legislation will negatively affect industry profitability over the next few years, new innovations within the healthcare field have maintained an influx of new interest to the industry. Combining medical technology with human touch, the healthcare industry diagnoses, treats, and administers care around the clock -- responding to the needs of millions of people. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology.

World Street Fundamentals has highlighted Osiris Therapeutics, Inc. as a stem cell therapeutic company. It focuses on developing and marketing products to treat serious medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. The Company's biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials, including for Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure. Prochymal is also being developed for the repair of heart tissue following a heart attack and for protection of pancreatic islet cells in patients with type I diabetes. The entire report on Osiris Therapeutics, Inc. (NASDAQ: OSIR) is available here:

World Street has highlighted Biogen Idec Inc. as a global biotechnology company focused on discovering, developing, manufacturing and marketing products for the treatment of neurological disorders and other serious diseases. Its marketed products address diseases: multiple sclerosis (MS), non-Hodgkin's lymphoma (NHL), rheumatoid arthritis (RA), Crohn's disease (CD), chronic lymphocytic leukemia (CLL) and psoriasis. Its primary source of other revenue is derived from royalties received on sales by its licensees of other products covered under patents that it owns. The entire report on Biogen Idec Inc. (NASDAQ: BIIB) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information